Risk of ischemic stroke and lifetime estrogen exposure

Neurology

Volumn 68, Issue 1, 2007, Pages 33-38

  De Leciñana, M Alonso ^a   Egido, J A ^b   Fernandez C ^b   Martinez Vila E ^c   Santos, S ^d   Morales, A ^e   Martinez E ^f   Pareja, A ^g   Alvarez Sabin J ^h   Casado, I ⁱ  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e Hospital Sta Maria del Rosell ^*  (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL ARNAU DE VILANOVA   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; EMBOLISM; FEMALE; GYNECOLOGICAL EXAMINATION; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESPAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MULTIVARIATE ANALYSIS; OBESITY; OVARY FUNCTION; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS;

EID: 33846107194     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000250238.69938.f5     Document Type: Article

References (46)

1. Hurn PD, Brass LM. Estrogen and stroke: a balanced analysis. Stroke 2003;34:338-341.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
3. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-626.
4. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996;10:615-624.
5. Wang Q, Santizo R, Baughman VL, Pelligrino DA, Iadecola C. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke 1999;30:630-637.
6. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
7. Brass LM. Hormone replacement therapy and stroke. Clinical trials review. Stroke 2004;35(suppl 1):2644-2647.
8. Baron YM, Galea R, Brincat M. Carotid artery wall changes in estrogen-treated and untreated postmenopausal women. Obstet Gynecol 1998;91:982-986.
9. Jonas HA, Kronmal RA, Psaty BM, et al. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study. Ann Epidemiol 1996;6:314-323.
10. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D. Estrogen replacement therapy and progression of intimamedial thickness in the carotid arteries of postmenopausal women. ACAPS investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol 1995;142:1011-1019.
11. Akkad A, Harsthorne T, Bell PR, al-Azzawi F. Carotid plaque regression on oestrogen replacement: a pilot study. Eur J Vasc Endovasc Surg 1996;11:347-348.
12. Nabulsi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities. (ARIC) Study Investigators. Circulation 1996;94:1857-1863.
13. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergström R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153:1201-1209.
14. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement and risk of non-fatal stroke. Lancet 1997;350:1277-1283.
15. Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestagen as hormone replacement therapy. Stroke 1998;29:23-28.
16. Groodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
17. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
18. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-642.
19. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen replacement after ischemic stroke. N Engl J Med 2001;345:1243-1249.
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
21. Nelson HD, Humphrey LL, Nygren P, Teustch SM, Allan JD. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002;288:872-881.
22. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005;330:342-345.
23. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/ American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617.
24. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch Int Med 1993;153:154-183.
25. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
26. Summary of the Second Report on the National Cholesterol Education Program (NCEP). Expert Panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
27. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(suppl 7):1-96.
28. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
29. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
30. Cote R, Battista RN, Wolfson C, Boucher J, Adam J, Hachinski VC. The Canadian Neurological Scale: validation and reliability assessment. Neurology 1989;39:638-643.
31. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
32. Bushnell CD. Oestrogen and stroke in women: assessment of risk. Lancet Neurol 2005;4:743-751.
33. Walsh BW. The effects of estrogen and selective estrogen receptor modulator on cardiovascular risk factors. Ann NY Acad Sci 2001;949:163-167.
34. Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med 2005;5:25-33.
35. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-230.
36. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol 1997;50:475-479.
37. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: The Adventist Health Study. J Clin Epidemiol 1999;52:303-307.
38. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf I. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155:339-345.
39. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066.
40. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. A prospective-study of age at menarche, parity, age at 1st birth, and coronary heart-disease in women. Am J Epidemiol 1987;126:861-870.
41. Snowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health 1989;79:709-714.
42. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and stroke mortality. Cohort study with 3561 stroke deaths during 37-year follow-up. Stroke 2004;35:1548-1551.
43. Hahn RA, Eaker E, Rolka H. Reliability of reported age at menopause. Am J Epidemiol 1997;146:771-775.
44. Den Tonkelaar I. Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas 1997;27:117-123.
45. Bean JA, Leeper JD, Wallace RB, Sherman BM, Jagger H. Variations in the reporting of menstrual histories. Am J Epidemiol 1979;109:181-185.
46. Colditz GA, Stampfer MJ, Willet WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987;126:319-325.